[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cerebral-small-vessel-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cerebral-small-vessel-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,44,76,101,126,153,177,211,238,266,288,310,333,358],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100466620","phase-2-glp-1-analogue-in-preventing-progression-of-small-vessel-disease-gapp-svd-100466620",false,"NCT05356104","GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)","GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD) - A Pilot Study","GAPP-SVD","Inclusion Criteria:\n\n1. Chinese ethnicity;\n2. Age 55 to 80 years old;\n3. Age-Related White Matter Change (ARWMC) Scale of 2 or early 3 in FLAIR MRI;\n4. Modified Functional Ambulation Classification 5 or above;\n5. Montreal Cognitive Assessment (MoCA) score \\\u003C 25;\n6. Both diabetic and non-diabetic patient are eligible;\n7. Patient who understands the purpose and requirements of the study, and able to provide an informed consent;\n\nExclusion Criteria:\n\n1. Dementia or MoCA score lower than 2nd percentile of the age and education adjusted cutoff ;\n2. Cerebral white matter changes unrelated to neurodegenerative, e.g. CADASIL, X-linked adrenoleukodystrophy, metabolic diseases, multiple sclerosis, etc.;\n3. Contraindication to GLP-1R agonist, including thyroid carcinoma, pancreatic pathology, proliferative retinopathy, hypersensitivity to GLP-1R agonist and history of family history of multiple endocrine neoplasia;\n4. BMI \\\u003C18.5kg\u002Fm2;\n5. Contraindication to proposed imaging, e.g. chronic kidney disease (KDNIGO) stage 4 or above, acute kidney injury, hypersensitivity to gadolinium-based contrast, non-MRI conditional implants or prosthesis;\n6. Medical condition that would not allow the patient to adhere to the protocol or complete the study.;\n7. Patient with established neurodegenerative disorders (e.g. Parkinson's Disease, Alzheimer's Disease, etc.);\n8. Pregnancy.","ALL","55 Years","80 Years",{"count":21,"type":22},110,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Cerebral small vessel disease (cSVD), a result of neurovascular cell dysfunction, is a major cause of stroke, dementia and mobility problems worldwide. Vascular risk factor control alone may not be sufficient to prevent the development of vascular cognitive impairment (VCI) in patients with cSVD according to previous clinical trials.\n\nThe presence of glucagon-like peptide-1 receptor (GLP-1R) in cerebral microglia may reveal a potential therapeutic target for prevention of cSVD progression and its disabling clinical outcomes. At the cellular and animal experimentation levels, GLP-1R agonist demonstrated reversal of some pathogenic processes in cSVD. However, its application to cSVD patients remains to be elucidated.\n\nInvestigator aims to investigate the safety and efficacy of GLP-1R agonist in patients with moderate-to-severe cSVD.",[28],"Cerebral Small Vessel Disease",[30],"cSVD","RECRUITING","2026-06-03",{"date":34,"type":35},"2026-06-05","ACTUAL",{"date":37,"type":35},"2022-05-25",{"date":39,"type":22},"2027-12",{"name":41,"class":42},"Chinese University of Hong Kong","OTHER",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":55,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100638674","cerebral-small-vessel-disease-progression-dependent-on-stroke-type-100638674","NCT07611136","Cerebral Small Vessel Disease Progression Dependent on Stroke Type","Biomarker-based Assessment of Cerebral Small Vessel Disease Progression After Lacunar and Territorial Stroke - a Prospective Cohort Study","ZMA_BIO","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Evidence of cerebral small vessel disease on brain MRI, defined as white matter hyperintensities (Fazekas grade 1-3)\n* Assignment to one of the following study groups based on MRI findings:\n* cerebral small vessel disease without evidence of an acute ischemic stroke\n* cerebral small vessel disease with acute lacunar ischemic stroke\n* cerebral small vessel disease with acute territorial ischemic stroke\n* Ability to provide written informed consent\n* Sufficient German language skills to understand study procedures and assessments\n\nExclusion Criteria:\n\n* Alternative plausible causes of white matter hyperintensities other than cerebral small vessel disease (e.g. inflammatory central nervous system disorders, leukodystrophies, brain tumors)\n* Known neurodegenerative diseases (e.g. Parkinson's disease, Alzheimer's disease, other dementias)\n* Acute or recent traumatic brain injury\n* Contraindications to magnetic resonance imaging\n* Pregnancy or breastfeeding\n* Life expectancy of less than one year\n* Inability to comply with study procedures or follow-up visits","18 Years",{"count":54,"type":22},180,"1 Year","OBSERVATIONAL","The goal of this prospective, observational study is to understand if cerebral small vessel disease (CSVD) has different velocities and patterns of temporal development, dependent on a concurrent ischemic stroke. It focusses on adult patients with known or newly diagnosed CSVD on magnetic resonance imaging. The study will evaluate if blood based, in parts central nervous system specific protein markers, so called biomarkers, have an additional value reflecting the course of CSVD as defined per MRI assessments. Further patient-relevant endpoints include neuropsychological abilities, neurological functional outcomes, quality of life assessments, stroke recurrence risk.",[28,59,60,61],"Stroke","Stroke Recurrence","Biomarkers",[63,64,65],"cerebral small vessel disease","biomarkers","magnetic resonance imaging","2026-05-20",{"date":68,"type":35},"2026-05-28",{"date":70,"type":35},"2026-03-26",{"date":72,"type":22},"2028-04-01",{"name":74,"class":42},"Johannes Dorst",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":43},"100588935","puffins-brain-health-study-100588935","NCT06947876","PUFFINS Brain Health Study","Proving the Utility of Ultra-low Field MRI for Assessing Brain Health","PUFFINS BH","Inclusion Criteria:\n\n* Adults ≥ 50 years old.\n* Subjects who do not report problems with memory.\n* Small vessel disease (Fazekas score 1 to 3).\n* Suitable body habitus.\n* Able to understand written and spoken English.\n\nExclusion Criteria:\n\n* History of major stroke (minor stroke\u002FTransient Ischaemic Attacks or lacunar stroke are acceptable).\n* Individuals unable to give informed consent.\n* Contra-indications to MRI scanning such as implantable cardiac devices.","50 Years",{"count":86,"type":22},85,"Small vessel disease (SVD) is a major cause of stroke and contributor to dementia cases. As work continues to develop new treatments to address the impact of SVD, new imaging techniques are needed to identify and track the progression of brain changes that occur with SVD. Magnetic Resonance Imaging (MRI) is the gold standard to diagnose poor brain health due to small vessel disease. However, current MRI systems are expensive and complex to operate, and so access is limited.\n\nLow-field MRI technology, operating at magnetic field strengths many times lower than conventional MRI, can make brain imaging much more cost-effective and accessible. However, further work is needed to develop low-field MRI towards clinically feasible assessments of brain health. The University of Aberdeen hosts a unique network of researchers and imaging technologies that is now making it possible to test and develop different low-field MRI approaches towards solving key healthcare challenges.\n\nThe aim of this study is to evaluate the potential of two distinct approaches, field-cycling imaging (FCI) and ultra-low field MRI (ULF-MRI), to detect brain changes linked with small vessel disease. Automated methods will be developed to analyse images and extract measurements that detect and track progression of disease severity.",[28],[90,91],"Field-cycling imaging","Ultra-low field MRI","2026-05-04",{"date":94,"type":35},"2026-05-05",{"date":96,"type":35},"2025-12-17",{"date":98,"type":22},"2027-05",{"name":100,"class":42},"University of Aberdeen",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":107,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":4},"100634589","study-on-eye-brain-cross-organ-mapping-and-systemic-disease-association-based-on-multimodal-big-data-100634589","NCT07541651","Study on Eye-Brain Cross-Organ Mapping and Systemic Disease Association Based on Multimodal Big Data","Inclusion Criteria:\n\n* Eye data: Images must meet quality standards (no significant artifacts, key structures clearly visible), with complete examination records (including examination date and device model).\n* Brain data: MR images must be free of motion artifacts, with complete sequences (at least including T1-weighted imaging and MRA), and reports must confirm no technical issues.\n* Eye-brain paired cohort: Must contain at least one type of eye image (including CFP, OCT, or OCTA) along with brain MR data, and be linkable to a unique identifier and clinical information in the database\n* Clinical data: Clinical information (such as core biochemical indicators, demographic information, and necessary questionnaire items) must have a missing rate ≤30%, with standardized and clear ICD diagnostic codes, complete laboratory test data, and medical order information (including medication or follow-up recommendations)\n* Prior to initial inclusion in the study, participants must have no history of severe organic diseases (including non-curable or end-stage malignancies, severe heart failure (NYHA Class III-IV), end-stage renal disease (CKD Stage 5), decompensated cirrhosis, or significant functional impairment due to severe cerebrovascular disease sequelae, etc.).\n\nExclusion Criteria:\n\n* Ocular examinations in which key features cannot be identified due to conditions such as cataracts or vitreous hemorrhage brain MR images deemed unacceptable in quality due to factors such as metal implants\n* Clinical information (including core biochemical indicators, demographic details, essential questionnaire items, etc.) with a missing rate exceeding 30%\n* Individuals who are pregnant or lactating, those with ocular trauma, congenital ocular malformations, or severe organic diseases.",true,{"count":109,"type":22},208000,"This project integrates multimodal eye data (CFP, OCT, OCTA) from 50,000 cases, brain MR data from 150,000 cases, and ICD diagnoses, medical orders, and test results from an eye-brain paired cohort of 8,000 cases to construct an eye-brain cross-modal mapping model and an eye-brain-systemic disease association model. It aims to clarify the quantitative associations between multimodal ocular features and brain structural and vascular characteristics as well as systemic disease ICD diagnoses, thereby uncovering the cross-organ and cross-modal linkage mechanisms between the eye and brain. Ultimately, it seeks to achieve mapping and prediction of brain imaging features based on ocular data, enable ocular-based diagnosis and prediction of various diseases, and contribute significantly to early disease screening, risk stratification, and optimization of clinical diagnosis and treatment.",[112,113,114,28,115],"Cataract","Vitreous Hemorrhage","Diabetic Eye Diseases","Cerebrovascular Stenosis","NOT_YET_RECRUITING","2026-04-14",{"date":119,"type":35},"2026-04-21",{"date":121,"type":22},"2026-04-25",{"date":123,"type":22},"2029-12-31",{"name":125,"class":42},"Beijing Friendship Hospital",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":134,"maxAge":19,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":137,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":75},"100617356","remote-ischemic-conditioning-for-cognitive-impairment-in-cerebral-small-vessel-disease-100617356","NCT07317557","Remote Ischemic Conditioning for Cognitive Impairment in Cerebral Small Vessel Disease","Mechanisms of Remote Ischemic Conditioning in Preventing and Treating Cognitive Impairment in Cerebral Small Vessel Disease","RIC-CSVD","Inclusion Criteria:\n\n* Age 30-80 years.\n* Diagnosis of cerebral small vessel disease according to the Chinese Guidelines for the Diagnosis and Treatment of Cerebral Small Vessel Disease (2020).\n* Mild cognitive impairment with a Montreal Cognitive Assessment (MoCA) score of 18-25.\n* The patient or a legally authorized representative is able and willing to sign written informed consent.\n\nExclusion Criteria:\n\n* Any condition that is unsuitable for remote ischemic conditioning, including soft tissue injury, limb deformity or vascular injury in the upper limb, bleeding disorders, or systolic blood pressure \\> 200 mmHg.\n* History or presence of neurological or psychiatric disorders that may interfere with participation or outcome assessment, such as other cerebrovascular diseases, Parkinson's disease, or major depressive disorder.\n* Current or past severe systemic diseases deemed inappropriate for the study by the investigator, including but not limited to severe cardiovascular diseases (e.g., congestive heart failure, severe arrhythmia, myocardial infarction), severe hepatic diseases (e.g., cirrhosis), severe renal diseases (e.g., requiring hemodialysis or peritoneal dialysis), hematologic diseases with bleeding tendency (e.g., hemophilia), poorly controlled diabetes (blood glucose \\> 16.8 mmol\u002FL or \\\u003C 2.8 mmol\u002FL) or with severe complications, active or uncontrolled systemic autoimmune diseases or primary\u002Fsecondary immunodeficiency, or malignancy.\n* Laboratory abnormalities, including absolute neutrophil count \\\u003C 1.5 × 10⁹\u002FL, platelet count \\\u003C 100 × 10⁹\u002FL, hemoglobin \\\u003C 90 g\u002FL, AST or ALT \\> 2.5 × upper limit of normal (ULN), total bilirubin \\> 1.5 × ULN, or serum creatinine \\> 1.5 × ULN.\n* Coagulation abnormalities, including for patients not on anticoagulant\u002Fantithrombotic therapy: INR \\> 1.7 or APTT \\> 1.25 × ULN; and for patients on anticoagulant\u002Fantithrombotic therapy: INR \\> 3.0 or APTT \\> 1.5 × ULN.\n* Positive tests for hepatitis B with detectable HBV-DNA, or positive serology for hepatitis C, syphilis (TPAb\u002FRPR), or HIV.\n* Pregnant or breastfeeding women.\n* Contraindications to MRI (e.g., pacemaker or other metallic implants, severe claustrophobia).\n* Participation in another clinical trial within 3 months prior to enrollment.\n* Severe trauma or major surgery within 3 months before remote ischemic conditioning, or planned surgery during the study period (except minor procedures and laparoscopic procedures performed within 4 weeks before baseline).\n* History of substance abuse or alcoholism within 1 year prior to enrollment.\n* Any other condition that may increase risk or interfere with the interpretation of study results, as judged by the investigator.","30 Years",{"count":136,"type":22},40,[138],"NA","This randomized, double-blind, sham-controlled trial aims to evaluate the effect of remote ischemic conditioning (RIC) on cognitive function in patients with cerebral small vessel disease-related mild cognitive impairment. Forty eligible participants will be randomized 1:1 to receive either RIC or sham RIC twice daily for 90 days in addition to standard medical therapy. The primary outcome is the change in Montreal Cognitive Assessment (MoCA) score from baseline to 90 days. Secondary outcomes include changes in white matter hyperintensity burden and diffusion tensor imaging metrics on MRI, EEG functional connectivity, and activities of daily living.",[28,141],"Cognitive Impairment",[143],"cerebral small vessel disease; cognitive impairment; remote ischemic conditioning; white matter hyperintensities; EEG functional connectivity","2026-03-06",{"date":146,"type":35},"2026-03-10",{"date":148,"type":22},"2026-04-01",{"date":150,"type":22},"2026-12-31",{"name":152,"class":42},"Jiangsu Province Nanjing Brain Hospital",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":107,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":162,"conditions":163,"keywords":164,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":75},"100621616","neural-correlates-eeg-and-fmri-of-gait-in-small-vessel-disease-100621616","NCT07372937","Neural Correlates (EEG and fMRI) of Gait in Small Vessel Disease","Investigating Neural Correlates of Gait Abnormalities in Patients With Cerebral Small Vessel Disease","doesn't exist","Inclusion Criteria:\n\n* Age 50 years or older.\n* Clinical and radiological diagnosis of cerebral small vessel disease (SVD), confirmed by MRI findings such as white matter hyperintensities, lacunes, or microbleeds.\n* Fazekas score 2 or 3 on MRI.\n* Presence of slowly progressive gait disturbance (e.g., slowness, imbalance, freezing) rather than acute stroke presentation.\n\n  * Ability to give informed consent and cooperate with testing procedures.\n\nExclusion Criteria:\n\n* Presence of other neurodegenerative disorders (e.g., Parkinson's disease, Alzheimer's disease).\n* History of large vessel stroke or intracerebral hemorrhage.\n* Contraindications to MRI (e.g., pacemaker, metallic implants, severe claustrophobia).\n* Severe cognitive impairment that prevents participation (MoCA \\\u003C10).\n* Musculoskeletal or orthopedic causes of gait disturbance not related to neurological dysfunction.",{"count":136,"type":22},"What is the purpose of this study? This observational study is being done to understand how cerebral small vessel disease (SVD) affects walking and balance. SVD is a common brain condition in older adults that damages small blood vessels. It can lead to problems with movement, thinking, and memory. The researchers want to find out how changes in brain activity and connectivity contribute to walking difficulties in people with SVD.\n\nWhy is this study important? Walking and balance problems increase the risk of falls and loss of independence. By studying brain activity during walking-related tasks, researchers hope to identify patterns that explain why these problems happen. This knowledge could help develop better rehabilitation methods in the future.\n\nWho can participate? Adults over 50 years old with cerebral small vessel disease and gradual gait problems may be eligible. Healthy adults of similar age without neurological problems may also take part as control participants.\n\nWhat will happen in this study?\n\nParticipants will:\n\nComplete walking, balance, and cognitive tests such as the Timed Up and Go, Berg Balance Scale, and Montreal Cognitive Assessment.\n\nUndergo brain imaging (MRI) to confirm the diagnosis and study brain structure and function.\n\nHave an EEG recording while resting and while watching short videos showing walking and turning movements.\n\nA smaller group will also undergo functional MRI (fMRI) while watching the same videos.\n\nThe MRI and EEG results will be analyzed to see how brain networks involved in movement and balance differ between patients and healthy adults.\n\nHow long will the study take? The study will take about two years to complete. Each participant's visit will last approximately two to three hours in total.\n\nWhat are the possible benefits? There may be no direct benefit to participants. However, this study may help researchers understand how small vessel disease affects brain function related to walking, which may improve care for future patients.",[28],[165,166,167],"Gait Disturbances, Vascular cognitive impairment","gait disturbances","vascular cognitive impairment","2026-01-31",{"date":170,"type":35},"2026-02-03",{"date":172,"type":22},"2026-03-01",{"date":174,"type":22},"2027-03-01",{"name":176,"class":42},"Ain Shams University",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":23,"phases":187,"briefSummary":188,"conditions":189,"keywords":191,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":75},"100598217","neurophysiological-and-behavioral-study-of-the-cognitive-deficits-associated-with-cerebral-small-vessel-disease-in-the-shiva-cohort-shiva-cogneurophys-100598217","NCT07068620","Neurophysiological and Behavioral Study of the Cognitive Deficits Associated With Cerebral Small Vessel Disease in the SHIVA Cohort. SHIVA-CogNeurophys","Neurophysiological and Behavioral Study of the Cognitive Deficits Associated With Cerebral Small Vessel Disease in the SHIVA Cohort - SHIVA-CogNeurophys","SHIVA-CogNeuro","Inclusion Criteria:\n\n* Patients included or previously included in the SHIVA cohort\n* Basic computer skills (ability to open a browser, use a mouse and keyboard)\n* Access to a personal computer with an internet connection\n* Independent in Activities of Daily Living (ADL) with a score ≥ 5\u002F6, and in Instrumental Activities of Daily Living (IADL) with a score ≥ 4\u002F8\n* Informed and written consent signed by the participant and the investigating physician for this study\n\nExclusion Criteria:\n\n* Motor impairments preventing the use of a keyboard and mouse (e.g., motor issues related to severe hand osteoarthritis)\n* Depressive symptoms indicated by a score of 2 to 4 on the mini Geriatric Depression Scale (mini GDS), which includes 4 items\n* Age-related macular degeneration (AMD)\n* Untreated glaucoma\n* Untreated psychiatric conditions that interfere with cognitive assessments\n* Diagnosed attention deficit disorder with or without hyperactivity or patients who could not complete all cognitive tests required in the SHIVA cohort\n* Systemic diseases that cause cognitive changes, such as obesity and metabolic disorders\n* History of epilepsy or seizures\n* Scalp sensitivity or skin lesions (dermatitis, wounds, etc.)\n\nContraindications for the use of electrical stimulation:\n\n* Surgical clips, metal sutures, staples, stents\n* Osteosynthesis material in the head or neck\n* Pacemaker\n* Implanted hearing aid\n* Ocular foreign bodies, shrapnel, bullets\n* Metalworker\n* Pacemaker or neurostimulator\n* Heart valve or endovascular material\n* Ventricular shunt valve\n\n  * Recent exposure (\\\u003C 6 months) to brain stimulation (tDCS, TMS, etc.)\n  * Ongoing participation in a clinical trial or cognitive training program",{"count":186,"type":22},80,[138],"Cerebral small vessel disease (cSVD) is characterized by an alteration of the structure and function of small penetrating brain arteries. Highly prevalent in older individuals from the general population, it represents a leading cause of stroke and a major contributor to cognitive decline and risk of dementia.\n\nBetter detection and management of covert cSVD would have a major impact on preventing disability and costs related to stroke, cognitive impairment and dementia. The aim of the present study is to identify novel electroencephalographic (EEG) biomarkers of the cognitive deficits associated with cSVD, and how these biomarkers and cognitive performance are affected by personalized cognitive training or transcranial alternating current stimulation (tACS), a non-invasvie brain stimulation technique.",[28,59,190],"Cognitive Complaint",[192,193,194,195,196,197,198,199,200,201],"Cognitive decline","dementia","stroke","small vessel disease","healthy brain aging","electroencephalography","neuromodulation","transcranial alternating current stimulation","cognitive training","cognitive rehabilitation","2026-01-30",{"date":204,"type":35},"2026-02-02",{"date":206,"type":35},"2025-08-07",{"date":208,"type":22},"2028-03-07",{"name":210,"class":42},"University Hospital, Bordeaux",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":17,"minAge":218,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":23,"phases":221,"briefSummary":222,"conditions":223,"keywords":225,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":237},"100621455","vr-training-to-improve-postoperative-cognitive-function-in-elderly-patients-with-cerebral-small-vessel-disease-undergoing-non-cardiac-surgery-100621455","NCT07370844","VR Training to Improve Postoperative Cognitive Function in Elderly Patients With Cerebral Small Vessel Disease Undergoing Non-Cardiac Surgery","A Prospective Randomized Controlled Trial of VR Training to Improve Postoperative Cognitive Function in Elderly Patients With Cerebral Small Vessel Disease Undergoing Non-Cardiac Surgery","Inclusion Criteria:\n\n1. Age≥60;\n2. Preoperative MRI-confirmed cerebral small vessel disease;\n3. Scheduled to undergo non-cardiac, non-craniotomy procedures under general anesthesia;\n4. ASA physical status classification: I-III;\n5. No use of cognitive-enhancing medications within 3 months prior to surgery;\n6. Voluntary participation with signed informed consent\n\nExclusion Criteria:\n\n1. Contraindications to cranial MRI (e.g., cardiac pacemaker, metallic implants, etc.);\n2. Intolerance to VR equipment during pre-training adaptation (e.g., dizziness, nausea, vomiting, or other subjective discomfort);\n3. Severe visual or auditory impairment;\n4. Severe hepatic or renal dysfunction;\n5. Pre-existing neuropsychiatric disorders (e.g., schizophrenia, epilepsy, Parkinson's disease, or active delirium);\n6. Inability to complete preoperative neuropsychological assessments (e.g., dementia, deaf-mutism, or communication barriers);\n7. Use of sedatives, antidepressants, or history of psychoactive substance abuse\u002Falcoholism","60 Years",{"count":220,"type":22},240,[138],"This clinical study aims to investigate whether virtual reality (VR)-based cognitive training can help improve postoperative cognitive function in elderly non-cardiac surgery patients with pre-existing cerebral small vessel disease (CSVD). As the global aging population undergoes an increasing number of surgical procedures, perioperative neurocognitive disorders (PND) have emerged as a serious complication among surgical patients, potentially prolonging hospital stays and increasing the risk of developing Alzheimer's disease. The study employs an innovative VR system that integrates eye-tracking cognitive assessment with interactive rehabilitation games to evaluate and train patients' cognitive function prior to non-cardiac and non-cranial surgeries. Conducted at Peking University Third Hospital, Peking University First Hospital, and Xuanwu Hospital of Capital Medical University, this research specifically targets patients undergoing general surgery, orthopedic surgery, and other non-cranial\u002Fnon-cardiac procedures. It seeks to validate whether this technology-based intervention can effectively enhance postoperative cognitive function in this population while exploring its underlying mechanisms. The findings may offer a practical solution for protecting cognitive health in elderly patients during recovery from routine surgical procedures.",[28,224],"Postoperative Cognitive Function",[28,224,226,227],"Postoperative Delirium","Virtual Reality","2026-01-21",{"date":230,"type":35},"2026-01-27",{"date":232,"type":22},"2026-02-01",{"date":234,"type":22},"2027-12-31",{"name":236,"class":42},"Peking University Third Hospital",3,{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":17,"minAge":134,"maxAge":19,"enrollmentInfo":246,"targetDuration":4,"studyType":23,"phases":248,"briefSummary":250,"conditions":251,"keywords":253,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":75},"100567920","phase-3-treatment-of-acute-ischemic-stroke-with-edaravone-dexborneol-sublingual-tablets-in-small-vessel-disease-100567920","NCT06674460","Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease","Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease: A Randomized, Double-Blind, Placebo-Controlled Study","TASTE-SVD","1\\. Inclusion Criteria:\n\n1. Age: Between 30 and 80 years .\n2. MRI-confirmed recent small subcortical infarct (RSSI): A lesion in the small penetrating artery territory, detected as DWI hyperintensity and ADC hypointensity, with a maximum axial diameter ≤20 mm.\n3. White Matter Hyperintensity (WMH) Burden: Fazekas score ≥2 (total score range: 0-6).\n4. Time from Stroke Onset: ≤3 weeks from symptom onset to randomization.\n5. Pre-stroke Functional Status: Modified Rankin Scale (mRS) ≤1 before the index stroke.\n6. Cognitive Function: No prior diagnosis of cognitive impairment or dementia.\n7. Education Level: At least primary school education and capable of completing cognitive assessments as judged by the investigator.\n8. Contraception Requirements:Women of childbearing potential and male participants with female partners of childbearing potential must agree to use effective contraception during the study and 30 days after the last dose of the investigational drug.Female participants must have a negative pregnancy test before enrollment.\n9. Informed Consent: Participants or their legal representatives must voluntarily sign an informed consent form (ICF).\n\n2\\. Exclusion Criteria:\n\n1. Intracranial Hemorrhagic Diseases: Evidence of hemorrhagic stroke, epidural hematoma, subarachnoid hemorrhage, or other bleeding disorders detected by head imaging (MRI\u002FCT).However, hemorrhagic transformation may be assessed by the investigator for potential inclusion.\n2. Severe Consciousness Disturbance: NIHSS item 1a score \\>1 (indicative of significant impairment in consciousness).\n3. Cortical Infarcts or Other Brain Abnormalities:Co-existing cortical infarcts, hydrocephalus, or other non-vascular white matter diseases (e.g., multiple sclerosis, carbon monoxide poisoning-related leukoencephalopathy).\n4. Severe Carotid Artery Stenosis: Requiring surgical intervention (\\>50% stenosis).\n5. Systemic Conditions Affecting Cognition:Endocrine disorders, vitamin deficiencies, systemic autoimmune diseases that can cause cognitive impairment.\n6. Neurological Disorders Associated with Cognitive Decline:CNS infections, Creutzfeldt-Jakob disease, primary Parkinson's disease, epilepsy, brain tumors, or severe traumatic brain injury.\n7. Pre-existing Severe Psychiatric Disorders:Diagnosed with major depressive disorder, vascular cognitive impairment, Alzheimer's disease, Parkinson's disease dementia, Lewy body dementia, frontotemporal dementia, or any cognitive dysfunction unrelated to stroke.\n8. Severe Physical Disability or Language Impairment:Severe hemiplegia or aphasia that significantly affects cognitive assessment.\n9. Use of Cognitive-Enhancing Medications:Within 4 weeks prior to screening, including but not limited to:Cholinesterase inhibitors (donepezil, rivastigmine, galantamine), NMDA receptor antagonists (memantine),Other neuroprotective agents (sodium oligomannate, lecanemab)\n10. Severe Liver or Kidney Dysfunction:Active liver disease (acute hepatitis, chronic active hepatitis, cirrhosis) or ALT\u002FAST \\>2× ULN.\n11. Severe renal impairment (serum creatinine \\>1.5× ULN).\n12. Life Expectancy \\\u003C1 year due to severe systemic diseases.\n13. Contraindications to MRI:Participants with MRI-incompatible implants, severe claustrophobia, or inability to undergo MRI.\n14. Known Allergies:History of hypersensitivity to Dexborneol, natural borneol, edaravone, or any excipients (e.g., mannitol, copovidone, microcrystalline cellulose, silica, magnesium stearate).\n15. Pregnancy and Lactation:Pregnant or lactating women, or those planning pregnancy during the study period.\n16. Participation in Other Clinical Trials:Enrolled in another clinical trial within the last 30 days.\n17. Other Investigator-Determined Factors:Any other medical, psychological, or social condition that, in the investigator's judgment, makes the patient unsuitable for participation.",{"count":247,"type":22},600,[249],"PHASE3","This study is a multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of Edaravone Dexborneol Sublingual Tablets in patients with acute ischemic stroke due to small vessel disease (TASTE-SVD).\n\nThe study will enroll approximately 600 participants aged 30 to 80 years who have experienced a recent small subcortical infarct (RSSI) confirmed by MRI. Participants will be randomized in a 1:1 ratio into either the Edaravone Dexborneol Sublingual Tablets group or the placebo group, with a 24-week treatment period followed by a 28-week follow-up.\n\nThe primary endpoint is a hierarchical composite endpoint at week 24, including all-cause mortality, modified Rankin Scale (mRS) score ≥2, recurrent stroke, changes in MoCA score, and changes in VaDAS-Cog score.\n\nSecondary endpoints include additional functional and cognitive assessments at 24 and 52 weeks, as well as MRI markers of white matter hyperintensities, new infarctions, microbleeds, and brain atrophy. Safety assessments will include adverse events (AEs), treatment-related adverse events (TRAEs), and serious adverse events (SAEs).\n\nThe study aims to determine whether Edaravone Dexborneol Sublingual Tablets improve functional outcomes and cognitive performance in patients with small vessel disease-related stroke.",[28,252],"Ischemic Stroke",[254,63,255,256],"sublingual edaravone dexborneol","acute ischemic cerebral small vessel disease","cognition","2025-09-22",{"date":259,"type":35},"2025-09-26",{"date":261,"type":35},"2025-08-01",{"date":263,"type":22},"2028-10-01",{"name":265,"class":42},"Peking Union Medical College Hospital",{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":19,"enrollmentInfo":273,"targetDuration":4,"studyType":23,"phases":275,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":4},"100606816","phase-4-prevention-of-stroke-recurrence-and-disease-progression-in-cerebral-small-vessel-disease-with-cilostazol-100606816","NCT07180472","Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol","Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol: a Multicenter, Open-Label, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age between 18 and 80 years.\n2. Diagnosis of small artery occlusion ischemic stroke based on the TOAST classification, with symptom onset within the past 6 months.\n3. MRI findings indicating white matter hyperintensities, with Fazekas grade ≥2.\n4. mRS (modified Rankin Scale) score ≤2.\n5. CDR (Clinical Dementia Rating) score \\\u003C1.\n\nExclusion Criteria:\n\n1. Presence of other central nervous system (CNS) disorders, including CNS infections, immune-mediated or degenerative diseases, epilepsy, intracranial tumors, etc.\n2. History of drug or alcohol abuse, or severe psychiatric disorders.\n3. Diagnosis of malignant tumors.\n4. Severe hepatic dysfunction (alanine aminotransferase \\[ALT\\] or aspartate aminotransferase \\[AST\\] \\>3 times the upper limit of normal) or renal impairment (creatinine clearance \\\u003C25 mL\u002Fmin).\n5. Concomitant congestive heart failure.\n6. Systemic hemorrhagic disorders or bleeding tendency, including platelet count ≤100,000\u002Fmm³, coagulation abnormalities, gastrointestinal ulcers, or history of non-traumatic symptomatic intracranial hemorrhage.\n7. Conditions requiring long-term anticoagulation therapy, such as atrial fibrillation or deep vein thrombosis.\n8. Known allergy or contraindication to cilostazol, clopidogrel, or aspirin.\n9. Requirement for dual antiplatelet therapy during the study period (e.g., due to vascular stent implantation or symptomatic intracranial arterial stenosis).\n10. Inability to complete scale assessments or comply with long-term follow-up.\n11. Pregnancy, lactation, or planning to become pregnant.\n12. Participation in another interventional clinical trial.\n13. Any other condition deemed unsuitable for study participation by the investigator.",{"count":274,"type":22},632,[276],"PHASE4","This study is designed to evaluate whether cilostazol, an antiplatelet medication, is more effective and safer than aspirin or clopidogrel in preventing recurrent strokes and slowing disease progression in patients with cerebral small vessel disease (CSVD).\n\nCerebral small vessel disease is a common cause of lacunar stroke, cognitive decline, and long-term disability. Currently, aspirin and clopidogrel are widely used to prevent recurrent ischemic events, but their effectiveness in CSVD remains uncertain. Cilostazol has shown potential benefits in improving cerebral blood flow, protecting blood vessel walls, and reducing the risk of bleeding compared with traditional antiplatelet drugs.\n\nIn this randomized controlled trial, participants diagnosed with CSVD and recent lacunar stroke will be randomly assigned to receive cilostazol, aspirin, or clopidogrel. The main outcomes to be evaluated include the rate of recurrent ischemic stroke, progression of cognitive and functional impairment, MRI markers of CSVD (such as white matter hyperintensity, lacunes, microbleeds, and small infarcts), and safety outcomes including bleeding events.\n\nThe investigators hypothesize that cilostazol will reduce the risk of recurrent stroke and slow disease progression more effectively than aspirin or clopidogrel, with a comparable or lower risk of bleeding.\n\nBy comparing these three antiplatelet drugs in a rigorous, multicenter randomized controlled trial, this study will provide important clinical evidence to guide personalized treatment strategies for patients with CSVD. The results are expected to improve long-term outcomes, reduce disability, and enhance the quality of life for stroke survivors.",[28],"2025-09-17",{"date":281,"type":35},"2025-09-23",{"date":283,"type":22},"2025-09-20",{"date":285,"type":22},"2027-12-01",{"name":287,"class":42},"First Affiliated Hospital of Chengdu Medical College",{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":107,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":296,"targetDuration":298,"studyType":56,"phases":4,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":4},"100600132","biomarkers-risk-assessment-imaging-and-neurodegeneration-in-cerebral-small-vessel-disease-brain-csvd-100600132","NCT07093515","Biomarkers, Risk Assessment, Imaging, and Neurodegeneration in Cerebral Small Vessel Disease (BRAIN-CSVD)","A Cohort Study of Biomarkers, Risk Assessment, Imaging, and Neurodegeneration in Patients With Cerebral Small Vessel Disease","BRAIN-CSVD","Inclusion Criteria:\n\n* Age \\>= 18 years old;\n* Cerebral small vessel disease on MR imaging.\n\nExclusion Criteria:\n\n* Cerebral infarction (except lacunar infarcts), cerebral hemorrhage, brain tumors, epilepsy, severe traumatic brain injury, or prior brain surgery;\n* Secondary white matter hyperintensities due to inflammatory, toxic causes and so on;\n* Contraindications to MRI.",{"count":297,"type":22},500,"5 Years","The BRAIN-CSVD study is a single-center prospective cohort study focusing on cerebral small vessel disease (CSVD).Patients enrolled in this research will undergo assessments for vascular risk factors, cognitive and other neurological functions, neuroimaging, and biomarkers. The study aims to explore imaging and biomarker predictors of CSVD progression, and the pathophysiological mechanisms of CSVD.",[28],"2025-07-29",{"date":303,"type":35},"2025-07-30",{"date":305,"type":22},"2025-10",{"date":307,"type":22},"2032-12-30",{"name":309,"class":42},"Zhejiang Hospital",{"id":311,"slug":312,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":107,"sex":17,"minAge":84,"maxAge":316,"enrollmentInfo":317,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":319,"conditions":320,"keywords":321,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":75},"100494248","correlation-between-deep-medullary-veins-and-cognitive-dysfunction-in-cerebral-small-vessel-disease-100494248","NCT05715710","Correlation Between Deep Medullary Veins and Cognitive Dysfunction in Cerebral Small Vessel Disease","1. Inclusion Criteria\n\n   1. Age 50 \\~ 85 years old.\n   2. The diagnostic criteria of CSVD patients with cerebral small vessel diseases should be in accordance with the 2015 Chinese Consensus on the diagnosis and treatment of cerebral small vessel Diseases formulated and recommended by the Cerebrovascular Division of Chinese Society of Neurology, Chinese Medical Association. MRI examination revealed the presence of one or more of the major imaging features of CSVD as proposed by the 2013 International Standards Reporting Group on Neuroimaging of Vascular Changes.\n   3. No large vessel stenosis (stenosis rate \\> 50%) was found after head and neck vascular examination (CTA, MRA, DSA or TCD combined with carotid ultrasound).\n   4. The vital signs are stable and can cooperate with the examination.\n   5. Informed consent signed by the patient or legal representative.\n2. Exclusion Criteria:\n\n   1. Cerebral infarction or cerebral hemorrhage caused by large vascular disease; And CTA\u002FMRA of the head and neck showed great vessel stenosis (stenosis rate \\> 50%).\n   2. Patients with secondary white matter lesions caused by poisoning, inflammation, tumor and other pathological changes.\n   3. Cognitive impairment and gait impairment caused by other causes (such as Alzheimer's disease, Parkinson's disease, depression, etc.\n   4. Patients with contraindications of magnetic resonance examination.\n   5. Illiterate or unable to cooperate with cognitive assessment due to severe hearing and visual impairment.","85 Years",{"count":318,"type":22},200,"This study aims to obtain the characteristics of cognitive impairment and imaging characteristics of patients with Cerebral small vessel disease (CSVD) through comprehensive and standardized neuropsychological assessment and multimodal imaging examination. The focus is to obtain the characteristics of cognitive impairment and imaging characteristics of patients with CSVD through 3.0T MRI SWI sequence. deep medullary veins (DMVs) were measured. To compare the demographic data, hematological indexes, imaging scores and the number of DMVs between CSVD groups with and without cognitive impairment, and to explore the correlation between deep medullary veins and cognitive dysfunction in cerebral small vessel disease.",[28],[322,323,63],"deep medullary veins","csvd","2025-01-23",{"date":326,"type":35},"2025-01-28",{"date":328,"type":35},"2022-01-01",{"date":330,"type":22},"2025-12-01",{"name":332,"class":42},"Zigong No.1 Peoples Hospital",{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":337,"acronym":4,"eligibilityCriteria":338,"healthyVolunteers":107,"sex":17,"minAge":339,"maxAge":4,"enrollmentInfo":340,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":342,"conditions":343,"keywords":344,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":75},"100567395","intelligent-analysis-and-clinical-validation-of-cerebral-small-vessel-disease-on-magnetic-resonance-imaginga-multi-center-study-100567395","NCT06667635","Intelligent Analysis and Clinical Validation of Cerebral Small Vessel Disease on Magnetic Resonance Imaging：A Multi-center Study","Inclusion Criteria:\n\n* ① Men and women age 40 years or older;\n\n  * At least one vascular risk factor has been identified, including hypertension, diabetes, hyperlipidemia, coronary heart disease, and chronic kidney disease；\n\n    * The patient performed two brain MRI Examinations simultaneously at a time interval of more than 6 months (≥6).\n\nExclusion Criteria:\n\n* ① The patient had no vascular risk factors；\n\n  * No clinical follow-up images;\n\n    * There are significant motion artifacts in the image, which cannot meet the","40 Years",{"count":341,"type":22},1000,"Cerebral small vessel disease (CSVD) accounts for 20% of ischemic strokes and is the most common cause of vascular cognitive impairment. Early identification of CSVD is critical for early intervention and improve clinical outcomes. Magnetic resonance imaging (MRI) may represent as a sensitive and robust tool to detect early changes in brain subtle structures and functions. The study is to investigate the comprehensive evaluation by using AI in early diagnosis and management of CSVD.",[28],[345,346,347,348],"Cerebral small vessel disease","Artificial intelligence","Deep learning","Magnetic resonance imaging","2024-10-30",{"date":351,"type":35},"2024-10-31",{"date":353,"type":22},"2024-11-01",{"date":355,"type":22},"2030-09-01",{"name":357,"class":42},"Chinese PLA General Hospital",{"id":359,"slug":360,"hasResults":11,"nctId":361,"briefTitle":362,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":107,"sex":17,"minAge":218,"maxAge":364,"enrollmentInfo":365,"targetDuration":4,"studyType":23,"phases":367,"briefSummary":368,"conditions":369,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":75},"100565502","targeting-18kda-translocator-protein-tspo-to-improve-brain-endothelial-cell-function-in-cerebral-small-vessel-disease-100565502","NCT06643013","Targeting 18kDa Translocator Protein (TSPO) to Improve Brain Endothelial Cell Function in Cerebral Small Vessel Disease","Inclusion Criteria:\n\nAged 60-90 years inclusive Male or postmenopausal female\n\n\\- Men are eligible to participate if they are willing to use the contraception methods listed in the PIS, during treatment and for 90 days after the last dose of treatment Able to provide written informed consent prior to any study-mandated procedures AA genotype at rs6971 (TSPO) locus Imaging-based diagnosis of cSVD (Fazekas score of at least 2 for periventricular and 2 for deep white matter) Mild cognitive impairment (MoCA 18-30) Willing to be genotyped at TSPO and ApoE loci\n\nInclusion Criteria (Healthy Volunteers):\n\nAged 60-90 years inclusive Male or female Able to provide written informed consent prior to any study-mandated procedures.\n\nWilling to be genotyped at TSPO and ApoE loci\n\nExclusion Criteria:\n\nHistory of clinical stroke History of frequent migraines Known Alzheimer's disease, lewy body disease or evidence of non-vascular neurological diseases Conditions affecting safe engagement in the intervention. Conditions preventing completion of study procedures, e.g. severe loss of vision or hearing Clinically-significant renal disease (eGFR \\\u003C30 ml\u002Fmin per 1.73m2) Clinically-significant elevation of serum transaminases or known clinically significant liver disease Contraindications to MRI scanning or exposure to gadolinium-based contrast agents Newly commenced (within 2 months of study start) statins, antihypertensives or antiplatelet treatments Severe respiratory disease with chronic hypoxia (sats \\\u003C92%), known CO2 retention or need for home oxygen therapy.\n\nUse of the following medications or therapies:\n\n* Severe and moderate P450 CY3A4 inhibitors: Boceprevir, Clarithromycin, Cobicistat, Idelalisib, Itraconazole, Ketoconazole, Nelfinavir, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole, Aprepitant, Conivaptan, Crizotinib, Diltiazem, Dronedarone, Erythromycin, Fluconazole, Imatinib, Isavuconazole, Nefazodone, Netupitant, Nilotinib, Posaconazole, Tofisopam, Verapamil, Delavirdine.\n* Severe and moderate P450 CY3A4 inducers: Carbamazepine, Enzalutamide, Fosphenytoin, Mitotane, Phenytoin, Rifampicin, Bosentan, Efavirenz, St John's wort, Barbiturates, Nevirapine, Primidone, Rifabutin, Rifapentine.\n* Oral contraceptives\n* Levothyroxine\n\nExclusion Criteria (Healthy Volunteers):\n\nContraindications to MRI scanning or exposure to gadolinium-based contrast agents Pregnant women of childbearing potential Clinically significant renal disease (eGFR \\\u003C30 ml\u002Fmin per 1.73m2) Severe respiratory disease with chronic hypoxia (sats \\\u003C92%), known CO2 retention or need for home oxygen therapy.","90 Years",{"count":366,"type":22},106,[138],"In healthy people, blood flow to particular areas in the brain increases when the area becomes more active. This ensures that the brain gets enough blood at the right place and time. In people with cerebral small vessel disease (cSVD), this process is disrupted, and the increased blood flow in response to activity is decreased or absent. Damage to the endothelial cells, that form the inner lining of blood vessels, is a key pathological process in cSVD. The aim of this study is to find out whether endothelial cell function and blood flow in cSVD can be improved by altering the function of a protein called TSPO. We will do this by using a drug called XBD173, which binds to TSPO.\n\nThis is a double-blind, randomised, crossover study. cSVD patients will be recruited from memory clinics at Imperial College Healthcare NHS Trust. Participants will be invited to the clinical research facility (CRF) at Hammersmith Hospital and randomised to receive XBD173 or matched placebo, twice daily, for 4 weeks. After a 6-week washout, they will be switched to receive the other intervention. The study visits will involve MRI scans and blood tests to assess endothelial cell function.\n\nHealthy volunteers will also be recruited for image optimisation and control data. They will attend for a single MRI scan and not receive XBD173.",[28],"2024-10-14",{"date":372,"type":35},"2024-10-15",{"date":374,"type":22},"2024-10",{"date":376,"type":22},"2028-04",{"name":378,"class":42},"Imperial College London"]